2008•American Journal of HematologyRequires access

CD8+ cutaneous T‐cell lymphoma successfully treated with bexarotene: A case report and review of the literature

Srivalli Gopaluni, Raiza Perzova, Lynn Abbott, Ramsey Farah, Anthony E. Shrimpton, R. Hutchison, Bernard J. Poiesz

Abstract

CD8+ cutaneous T-cell lymphoma (CTCL) is a relatively rare subset of the non-Hodgkins lymphomas. Bexarotene has been FDA-approved for the treatment of CTCL, but previous studies have been conducted on CD4+ CTL and there have been no reports about its use in CD8+ CTCL. Herein, we report on a patient whose CD8+ CTCL completely responded to treatment with bexarotene.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Bexarotene, Cutaneous T-cell lymphoma, Medicine, CD8, Mycosis fungoides, Lymphoma, Dermatology, Internal medicine